Strengthening Risk Stratification with the «Rule of 5 kPa»
One of the most significant updates in Baveno VIII is the reaffirmation of the «Rule of 5 kPa», which provides clinicians with a practical framework to assess the risk of liver-related complications.
Liver stiffness thresholds of 10 kPa, 15 kPa, 20 kPa and 25 kPa help stratify patients according to their risk of hepatic decompensation and liver-related mortality, regardless of the underlying liver disease etiology.
This standardized approach enables healthcare professionals to identify patients at higher risk earlier, optimize surveillance strategies, and support more informed treatment decisions.
Non-Invasive Assessment of Clinically Significant Portal Hypertension (CSPH)
The Baveno VIII Consensus further consolidates the role of LSM by VCTE combined with platelet count as the reference non-invasive approach for the assessment of clinically significant portal hypertension (CSPH).
The guidelines also support the use of validated predictive models such as:
– ANTICIPATE
– ANTICIPATE NASH
These tools help refine risk prediction and support personalized clinical management while reducing reliance on invasive procedures.
Together, VCTE-derived liver stiffness measurements, platelet count, and predictive algorithms provide a comprehensive framework to guide patient care across various stages of chronic liver disease.
Spleen Stiffness Measurement Expands Its Clinical Value
Another major advancement highlighted in Baveno VIII is the growing role of spleen stiffness measurement (SSM by VCTE at 100 Hz).
Used alongside liver stiffness assessment, SSM improves the ability to:
– Rule in or rule out CSPH
– Refine patient risk stratification
– Support clinical decision-making
– Reduce unnecessary endoscopic procedures
The consensus also recognizes the value of predictive models such as NICER, further strengthening the clinical utility of spleen stiffness assessment. Importantly, Baveno VIII now incorporates SSM into the evaluation of cirrhosis recompensation, reflecting its increasing importance in longitudinal patient monitoring.
Recompensation: A New Era in Chronic Liver Disease Management
One of the most forward-looking aspects of the updated guidelines is the integration of non-invasive criteria to assess recompensation. The recommendations identify the following markers as being associated with the resolution of clinically significant portal hypertension:
– LSM < 10 kPa
– LSM < 15 kPa combined with SSM < 25 kPa
This shift reflects a broader evolution in hepatology. Beyond identifying disease progression, clinicians can now use non-invasive tools to monitor treatment response, measure clinical improvement, and assess the potential reversal of disease-related complications.
Baveno VIII Introduces Dedicated Recommendations for Children
For the first time, the Baveno consensus includes dedicated recommendations for pediatric liver disease. The new statements acknowledge the clinical value of both liver stiffness and spleen stiffness measurements in children, supporting their use for:
– Risk assessment
– Disease monitoring
– Clinical follow-up
This inclusion represents an important step toward expanding access to non-invasive liver assessment across all patient populations.
From Risk Assessment to Recompensation: A Complete Non-Invasive Ecosystem
The Baveno VIII Consensus demonstrates how far non-invasive liver disease assessment has evolved in recent years. Today, clinicians can rely on a comprehensive ecosystem of validated tools, including:
– Liver stiffness measurement (LSM)
– Spleen stiffness measurement (SSM)
– Platelet count
– ANTICIPATE and ANTICIPATE NASH models
– NICER predictive model
Together, these solutions support clinical decision-making from initial risk evaluation through long-term patient monitoring and recompensation assessment.
Why This Matters for Clinical Practice
The updated recommendations reinforce a common goal shared across the hepatology community:
– Earlier identification of patients at risk
– More personalized disease management
– Reduced need for unnecessary invasive procedures
– Improved long-term outcomes for patients with chronic liver disease
Notably, the Baveno VIII recommendations are specific to vibration-controlled transient elastography (VCTE®). Other stiffness measurement methods are only referenced within the Research Agenda and are not incorporated into the validated clinical pathways presented throughout the guidelines.
Throughout the consensus document, liver stiffness measurement thresholds refer specifically to values obtained using VCTE®, the technology implemented in FibroScan®. As Baveno VIII further strengthens the role of non-invasive assessment in chronic liver disease management, FibroScan® remains the reference device implementing Vibration-Controlled Transient Elastography (VCTE®).
With validated liver and spleen stiffness measurements supporting key clinical decisions across the patient journey, FibroScan® continues to help clinicians assess risk, monitor disease progression, and evaluate clinical improvement without invasive procedures.
If it’s VCTE®, it’s FibroScan®.
Reference
1 Journal of Hepatology @2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
